
Joseph I Friedman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2653111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 2017, 49, 27-35.	21.4	838
2	White Matter Changes in Schizophrenia. Archives of General Psychiatry, 2003, 60, 443.	12.3	761
3	Diffusion Tensor Imaging Findings in First-Episode and Chronic Schizophrenia Patients. American Journal of Psychiatry, 2008, 165, 1024-1032.	7.2	227
4	The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biological Psychiatry, 1999, 46, 1243-1252.	1.3	177
5	A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry, 2002, 51, 349-357.	1.3	170
6	Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology, 2004, 174, 45-53.	3.1	164
7	Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biological Psychiatry, 1999, 45, 1-16.	1.3	139
8	Diffusion Tensor Imaging in Schizophrenia. Biological Psychiatry, 2006, 60, 1181-1187.	1.3	115
9	Guanfacine Treatment of Cognitive Impairment in Schizophrenia. Neuropsychopharmacology, 2001, 25, 402-409.	5.4	103
10	Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial Dysfunction. Biological Psychiatry, 2007, 62, 1396-1404.	1.3	89
11	Brain Imaging Changes Associated WithÂRisk Factors for Cardiovascular and Cerebrovascular Disease in AsymptomaticÂPatients. JACC: Cardiovascular Imaging, 2014, 7, 1039-1053.	5.3	82
12	The Effects of Hypertension and Body Mass Index on Cognition in Schizophrenia. American Journal of Psychiatry, 2010, 167, 1232-1239.	7.2	76
13	Cognition in schizophrenia. Current Psychiatry Reports, 2001, 3, 423-428.	4.5	74
14	Correlates of Change in Functional Status of Institutionalized Geriatric Schizophrenic Patients: Focus on Medical Comorbidity. American Journal of Psychiatry, 2002, 159, 1388-1394.	7.2	69
15	Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia. JAMA Psychiatry, 2021, 78, 510.	11.0	63
16	Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry, 2007, 7, 25.	2.6	61
17	Pharmacological Treatments of Non-Substance-Withdrawal Delirium: A Systematic Review of Prospective Trials. American Journal of Psychiatry, 2014, 171, 151-159.	7.2	57
18	Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. Biological Psychiatry, 2000, 47, 962-968.	1.3	56

Joseph I Friedman

#	Article	IF	CITATIONS
19	A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia. Journal of Clinical Psychopharmacology, 2008, 28, 59-63.	1.4	49
20	Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia. NeuroReport, 2008, 19, 1369-1372.	1.2	38
21	Potential Noradrenergic Targets for Cognitive Enhancement in Schizophrenia. CNS Spectrums, 2004, 9, 350-356.	1.2	32
22	Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy. Neuropsychopharmacology, 2011, 36, 1289-1295.	5.4	32
23	Modifiable factors associated with postoperative delirium after hip fracture repair. European Journal of Anaesthesiology, 2020, 37, 649-658.	1.7	29
24	Brodmann area analysis of white matter anisotropy and age in schizophrenia. Schizophrenia Research, 2011, 130, 57-67.	2.0	28
25	Copy Number Variation in Syndromic Forms of Psychiatric Illness: The Emerging Value of Clinical Genetic Testing in Psychiatry. American Journal of Psychiatry, 2017, 174, 1036-1050.	7.2	16
26	The effects of hypertension and body mass index on diffusion tensor imaging in schizophrenia. Schizophrenia Research, 2011, 130, 94-100.	2.0	8
27	A <scp>Multiâ€Phase</scp> Quality Improvement Initiative for the Treatment of Active Delirium in Older Persons. Journal of the American Geriatrics Society, 2021, 69, 216-224.	2.6	8
28	The Course of Functional Decline in Geriatric Patients With Schizophrenia. American Journal of Geriatric Psychiatry, 2003, 11, 610-619.	1.2	2
29	Pimavanserin in Dementia-Related Psychosis. New England Journal of Medicine, 2021, 385, 372-373.	27.0	1
30	Novel Imaging Strategies for Assessment of Cerebrovascular Involvement. Mount Sinai Journal of Medicine, 2012, 79, 674-682.	1.9	0
31	Reply. JACC: Cardiovascular Imaging, 2015, 8, 498.	5.3	0